Drug profile · INN
sapropterin dihydrochloride
SAPROPTERIN DIHYDROCHLORIDE
sapropterin dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE) is a phenylalanine-4-hydroxylase activator. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — sapropterin dihydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 20
- Data quality
- 0.89
Quick answer
sapropterin dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE) is a phenylalanine-4-hydroxylase activator. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phenylalanine-4-hydroxylase activator
Primary target: Phenylalanine-4-hydroxylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
Frequently asked questions
What is sapropterin dihydrochloride?
sapropterin dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE) is a phenylalanine-4-hydroxylase activator. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sapropterin dihydrochloride?
SAPROPTERIN DIHYDROCHLORIDE is a marketed brand name for sapropterin dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sapropterin dihydrochloride?
sapropterin dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.